Extended Data Fig. 5: Association of actionable biomarker status with DFS.
From: ctDNA-based molecular residual disease and survival in resectable colorectal cancer
a-b. Kaplan-Meier estimates for DFS stratified by the presence of genomic biomarkers among patients with pathological stage I-III colon cancer (a) and pathological stage IV colorectal cancer (b). *MSI high and TMB high lines overlap with each other. Two-sided Chi-square test for bar plots: P = 5.08 × 10−7 (a) c-d. Kaplan-Meier estimates for DFS stratified by MSI status (MSI High versus MSS; c) and TMB status (TMB high versus TMB low; d) for all patients in this cohort (N = 2,040). P = 9.47 × 10−9 (c); P = 2.96 × 10−9 (d). Two-sided Chi-square test for bar plots: P = 3.27 × 10−12 (c); P = 2.59 × 10−12 (d). Hazard ratios (HRs) and 95% CIs were calculated using the Cox proportional hazard model. P values were calculated using the two-sided log-rank test. This analysis was landmarked from the date of the MRD time point.
